Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Equity Ratio: 2010-2025

Historic Equity Ratio for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to -0.67.

  • Ironwood Pharmaceuticals' Equity Ratio rose 16.55% to -0.67 in Q3 2025 from the same period last year, while for Sep 2025 it was -0.67, marking a year-over-year increase of 16.55%. This contributed to the annual value of -0.86 for FY2024, which is 16.81% down from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Equity Ratio stood at -0.67, which was up 25.78% from -0.90 recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Equity Ratio registered a high of 0.61 during Q1 2023, and its lowest value of -1.02 during Q1 2025.
  • For the 3-year period, Ironwood Pharmaceuticals' Equity Ratio averaged around -0.65, with its median value being -0.75 (2024).
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Equity Ratio skyrocketed by 4,380.41% in 2021 and then crashed by 224.01% in 2023.
  • Ironwood Pharmaceuticals' Equity Ratio (Quarterly) stood at 0.54 in 2021, then grew by 10.25% to 0.59 in 2022, then plummeted by 224.01% to -0.74 in 2023, then decreased by 16.81% to -0.86 in 2024, then grew by 16.55% to -0.67 in 2025.
  • Its Equity Ratio was -0.67 in Q3 2025, compared to -0.90 in Q2 2025 and -1.02 in Q1 2025.